Call for Papers

Dear Colleagues,

You are invited to contribute a research article or a comprehensive review for consideration and publication in the *Journal of Personalized Medicine (JPM)* (ISSN 2075-4426). *JPM* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform.

Manuscripts prepared in Microsoft Word or LaTeX can be submitted to the Editorial Office online at www.mdpi.com. Detailed instructions for authors are also available online: www.mdpi.com/journal/jpm/instructions/

*JPM* is published in open access format—research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public can access the content free of charge as soon as it is published.

As an open access journal, *JPM* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. More information is available at: www.mdpi.com/about/apc/

We would be pleased to welcome you as one of our authors.

Prof. Dr. Stephen B. Liggett  
*Editor-in-Chief*

*JPM* Editorial Office  
E-Mail: jpm@mdpi.com  
Tel. +41 61 683 7734  
www.mdpi.com/journal/jpm/
Aims & Scope

*JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine. *JPM* recognizes that personalized medicine — the assessment of genetic, environmental and host factors that cause interindividual variability in disease risk, prognosis, and treatment — requires a transdisciplinary approach from a range of experts. For a comprehensive perspective of personalized medicine, *JPM* aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects.

We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.

Scope:

Topics of interest with a view towards personalized medicine include (but are not limited to) the following:

- ‘omics technologies (genomics, transcriptomics, proteomics, epigenomics, metabolomics, lipidomics, interferomics)
- next-generation sequencing developments and genome-wide association studies
- biomarker research, development and application
- drug target discovery and development
- bioethics
- pharmacoeconomics
- personalized health informatics (data mining, diagnosis, analysis)
- regulatory environments
- legal and social consequences of personalized medicine
- personalization of health interventions for improved safety, efficacy and sustainability. (e.g., drug therapy, nutrition) and variability in environment
- biochip/microarray technologies
- genetic testing, disease screening and molecular diagnostics for risk factors, preventative treatment and targeted therapy, and integration with therapy
- genetics and the biochemistry and physiology of drug action, uptake and metabolism; information for drug selection and dosage
- genetics based vaccine development
- genetics-based clinical trials methodology
- prediction-based drug safety; understanding adverse drug reactions
- bioinformatics (databases, data mining, modeling and simulation, signal/image analysis)
Open Access. What does it really mean?

Open access is mainly a response to what is known as the serials crisis: yearly increasing journal subscription prices, which make subscription-based journals increasingly difficult to afford.

Many university libraries around the world have had to cancel existing subscriptions, or are unable to keep up with subscribing to new journals, because the cost of publication has risen disproportionately to their budgets.

With open access publishing, the cost of peer-review and production of an article is borne by the institute of the author by payment of a one-time flat fee. Conversely, readers and their institutes are no longer charged for accessing the journals they need.

For researchers, open access brings the convenience of immediate access to the literature that they need — no matter for which university or company they work, or whether they just want to read a paper in their spare time at home.

For authors, open access means a much wider circle of readers due to the easy access to their research papers. The interested general public is also able to access research works, giving higher transparency to the outcome of taxpayer money spent on research.

Publication Ethics Statement

_JPM_ is a member of the Committee on Publication Ethics (COPE). _JPM_ takes the responsibility to enforce a rigorous peer-review together with strict ethical policies and standards to ensure to add high quality scientific works to the field of scholarly publication.
Editor-in-Chief

Prof. Dr. Stephen B. Liggett
University of South Florida (USA)
E-Mail: sliggett@health.usf.edu

Editorial Board

Ana Alfrevic
University of Liverpool
UK

Russ B. Altman
Clark Center MC Stanford
USA

Bruce J. Aronow
University of Cincinnati
USA

Paul N. Baird
Centre for Eye Research Australia
Australia

Michel G. Bergeron
Laval University
Canada

Alexandra I. F. Blakemore
Imperial College London
UK

Maged N. Kamel Boulos
University of the Highlands and Islands
UK

Lawrence C. Brody
National Human Genome Research Institute
USA

Jean-Michel Cardot
Université Blaise Pascal
France

Krassen Dimitrov
The University of Queensland
Australia

Roman Fleck
Index Ventures
Switzerland

Felix W. Frueh
University of North Carolina
USA

Pascale Gauthier
Biopharmaceutics Department
France

Yves A. Lussier
The University of Chicago
USA

Grant McArthur
Peter MacCallum Cancer Centre
Australia

Lori A. Orlando
Duke Center for Personalized Medicine
USA

Kathryn A. Phillips
UCSF, University of California
USA

Indra Neil Sarkar
University of Vermont
USA

Stephan W. Scherer
Hospital for Sick Children and
University of Toronto
Canada

Matthias Schwab
University Hospital Tuebingen
Germany

Uwe Siebert
University for Health Sciences
Austria

Mukesh Verma
National Institutes of Health (NIH)
USA

Wolfram Weckwerth
University of Vienna
Austria